Level C· Early human research exploring benefitsRetrospective StudyPubMed

Novel Combination Scalp Therapy for Androgenetic Alopecia: A Preliminary Retrospective Case Series with an Illustrative Four-Year Case.

Lee JH., Hahn HM.

Retrospective Study with a reported sample of 6 on Hair Loss, Hair Regeneration, published in J Clin Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
J Clin Med (2026)
Country
Switzerland
Reported sample size
6
Source database
PubMed
PMID
42452517
DOI
10.3390/jcm15135055

Abstract (original English)

Background/Objectives : Androgenetic alopecia (AGA) responds only partially to pharmacologic monotherapy. Combination procedural regimens incorporating platelet-rich plasma (PRP), stromal vascular fraction (SVF), and botulinum toxin (BTX) have been reported, but objective quantitative trichoscopic data on multimodal single-session protocols are limited. We retrospectively quantified the trichoscopic response to a four-component single-session scalp procedure used in routine clinical practice. Methods : Fifty-one consecutive AGA patients underwent a single-session procedure combining partial temporalis muscle resection with silicone implantation, negative-pressure scalp stimulation, and BTX, PRP, and SVF injections; 28 completed ≥ 4-month follow-up. Standardized 60× videodermoscopy at five predefined scalp locations was archived for paired quantitative analysis in six patients (30 location pairs, of which 28 were analyzable after excluding two pairs for motion artifact), with one additional patient imaged at four years. Six trichoscopic outcomes were derived by automated image analysis (Otsu thresholding, skeletonization, distance-transform shaft thickness); the primary analysis was performed at the patient level ( n = 6) and a supporting analysis at the panel level ( n = 28), each using paired Student's t -tests. Results : In the primary patient-level analysis ( n = 6 patients)

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research